Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06898281
Active, not recruiting Not applicable

Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papillary Muscles

NCT06898281 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Chest Hospital
Phase
Not applicable
Started
2025-03-23
Last updated
2025-04-24

Condition(s) studied

Premature Ventricular Contractions

Investigational drug(s) / intervention(s)

intracardiac echocardiography (ICE)-guided catheter ablationPressure-sensing catheter ablation alone

intracardiac echocardiography (ICE)-guided catheter ablation: Intracardiac echocardiography (ICE)-guided catheter ablation.

Pressure-sensing catheter ablation alone: Pressure-sensing catheter ablation alone

Study summary

This randomized, prospective, parallel, single-blind, multicenter clinical trial investigates the efficacy and safety of intracardiac echocardiography (ICE)-guided catheter ablation versus pressure-sensing catheter ablation alone in reducing PVC recurrence among patients with confirmed papillary muscle-originating premature ventricular contractions (PVCs). Participants were randomly allocated to either the ICE-guided intervention group or the conventional ablation control group following definitive diagnosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged ≥18 years. * Diagnosed with premature ventricular contractions (PVCs) originating from the papillary muscles. * Symptoms refractory to antiarrhythmic drug therapy. * Patients must be capable and willing to provide written informed consent for study participation. Exclusion Criteria: * History of cardiac surgery or any prior cardiac interventional procedures. * Ischemic heart disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy. * Severe hepatic or renal dysfunction: AST/ALT \>3× upper limit of normal (ULN); Serum creatinine (SCr) \>3.5 mg/dl or creatinine clearance (Ccr) \<30 ml/min. * Prior ablation for papillary muscle PVCs. * Life expectancy \<1 year. * Pregnancy or lactation.

Primary outcome measure(s)

  • Freedom from VC recurrence — Patients were followed up at 3 months postoperatively to assess recurrence.
    Freedom from VC recurrence (defined as a ≥80% reduction in VC burden, calculated as \[number of VCs per 24 hours / total number of heartbeats per 24 hours\] × 100%).

Trial sites (1)

FacilityCityRegionStatus
Shanghai Chest Hospital Shanghai Xuhui

More Shanghai Chest Hospital trials in China

Pulsed Field Ablation for the Treatment of Malignant Lung Tumors Starting soon
Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer Starting soon
Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation Starting soon
Association of Psychological Distress in Patients With Lung Cancer Recruiting
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors Recruiting

Other trials for the same condition

CHU Dual-Energy Ablation in Ventricular Arrhythmia Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06898281 on ClinicalTrials.gov ↗ ← All trials in China